A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
← catalyst calendarNCT06389526 · readout in 650 d
Sponsored by Coherus Oncology, Inc. (industry) · CHRS — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
48estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-15 | estimated | When the study began enrolling |
| Primary completion | 2028-05-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic Solid Tumors
Interventions
- Biological: CHS-1000
- Biological: Toripalimab — also filed as Loqtorzi, Toripalimab-tpzi
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-Emergent Adverse Events (TEAEs)
measured Up to approximately 27 months
Permalink · CHRS's whole pipeline · Catalyst calendar · Every registered study · What changed